

AD_____

Award Number: W81XWH-05-1-0064

TITLE: Modulation of TRAIL Cytotoxicity by Amiloride in Prostate Cancer

PRINCIPAL INVESTIGATOR: Ki Mo Kim
Young-Ho Kim

CONTRACTING ORGANIZATION: University of Pittsburgh
Pittsburgh, PA 15260

REPORT DATE: November 2006

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| REPORT DOCUMENTATION PAGE | | | | Form Approved OMB No. 0704-0188 | |
|---|-------------|----------------------------------|----------------------------|--|---|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. | | | | | |
| 1. REPORT DATE 01-11-2006 | | 2. REPORT TYPE Annual Summary | | 3. DATES COVERED 1 NOV 2004 - 31 OCT 2006 | |
| 4. TITLE AND SUBTITLE Modulation of TRAIL Cytotoxicity by Amiloride in Prostate Cancer | | | | 5a. CONTRACT NUMBER | |
| | | | | 5b. GRANT NUMBER W81XWH-05-1-0064 | |
| | | | | 5c. PROGRAM ELEMENT NUMBER | |
| 6. AUTHOR(S) Ki Mo Kim; Young-Ho Kim E-Mail: Kim0505@yahoo.com | | | | 5d. PROJECT NUMBER | |
| | | | | 5e. TASK NUMBER | |
| | | | | 5f. WORK UNIT NUMBER | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pittsburgh Pittsburgh, PA 15260 | | | | 8. PERFORMING ORGANIZATION REPORT NUMBER | |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 | | | | 10. SPONSOR/MONITOR'S ACRONYM(S) | |
| | | | | 11. SPONSOR/MONITOR'S REPORT NUMBER(S) | |
| 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited | | | | | |
| 13. SUPPLEMENTARY NOTES | | | | | |
| 14. ABSTRACT The challenge today is to develop a cytotoxic agent that selectively induces cytotoxicity in prostate cancer cells but avoids significant toxicity to the normal tissues. In this study, we will develop a novel strategy by using TRAIL in combination with amiloride. | | | | | |
| 15. SUBJECT TERMS TRAIL; PI3K; Amiloride; Na+/H+; DU-145; apoptosis; Akt; PDK-1 | | | | | |
| 16. SECURITY CLASSIFICATION OF: | | | 17. LIMITATION OF ABSTRACT | 18. NUMBER OF PAGES | 19a. NAME OF RESPONSIBLE PERSON |
| a. REPORT | b. ABSTRACT | c. THIS PAGE | | | USAMRMC |
| U | U | U | UU | 17 | 19b. TELEPHONE NUMBER (include area code) |

Table of Contents

| | <u>Page</u> |
|-----------------------------------|-------------|
| Introduction..... | 4 |
| Body..... | 6 |
| Key Research Accomplishments..... | 9 |
| Reportable Outcomes..... | 10 |
| Conclusion..... | NA |
| References..... | NA |
| Appendices..... | NA |

Introduction:

The long-term goal of our research project is to develop a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based therapy for prostate cancer. This translational research project is based on the observation that prostate cancer begins as an androgen-dependent tumor and undergoes clinical regression in response to pharmacological or surgical strategies that reduce testosterone concentration. While this treatment approach is effective initially in controlling the prostate cancer, these tumors ultimately fail to respond to androgen blockade. The failure of androgen ablation therapy leads to a hormone-refractory state of the disease. Androgen receptor mutations (6-10%) and amplifications (20-30%) may explain relapse in some patients (Bartlett et al., 2005). However, HER-2/neu overexpression has been reported in up to 67% of patients with hormone-refractory prostate carcinoma (Osman et al., 2001). Several studies have shown that overexpression of HER-2/neu is correlated with shortened patient survival, increased metastatic potential, and poor prognosis. This is probably because HER-2/neu promotes tumor survival through the PI(3)K-Akt signal transduction pathway. In this final report, we examined whether blockade of HER-2/neu-mediated tumor cell survival signals by quercetin, a common bioflavonoid present in many fruits and vegetables such as onions and apples, can sensitize prostate cancers to TRAIL-induced apoptotic death. The inhibition of HER-2/neu-mediated survival signals results in prevention of regrowth of prostate cancer.

The natural product quercetin (3,5,7,3',4'-pentahydroxyflavone), which is orally bioavailable, is a flavonoid found in many fruits and vegetables. Quercetin and its metabolites are potent antioxidants which have oxygen radical scavenging properties and inhibit xanthine oxidase and lipid peroxidation *in vitro* (Bors et al., 1994; Da Silva et al., 1998; Vulcain et al., 2005). Previous research has also shown that quercetin has anti-tumor, anti-inflammatory, anti-allergic, and anti-viral activities (Middleton, Jr. and Kandaswami, 1993; Kandaswami and Middleton, Jr., 1994; Wang, 2000; Nair et al., 2002; Suzuki et al., 2002). However, the molecular mechanisms underlying the anti-tumor effects are generally unknown. Several researchers have reported that quercetin inhibits PI(3)K with an IC₅₀ of 3.8 μ M (Matter et al., 1992; Yoshizumi et al., 2001). We examined whether the anti-tumor effects of quercetin, as manifested by its ability to selectively suppress colony formation by prostate cancer cells *in vitro*, are mediated by its ability to inhibit the PI(3)K-Akt signal transduction pathway.

Several researchers have observed a significant increase in HER-2/neu expression after the progression from hormone-dependent to hormone-independent disease (Osman et al., 2001; Signoretti et al., 2000). The expression of HER-2/neu is correlated with increased metastatic potential, poor prognosis in prostate cancer, and resistance to apoptosis (Signoretti et al., 2000). HER-2/neu (also known as ErbB2) is a gene in the epidermal growth factor receptor (EGFR) family (HER-1, HER-2, HER-3, HER-4). In many physiological contexts signaling through the HERs is induced by the formation of HER heterodimers, whose cytoplasmic tails are phosphorylated and coupled to SH2-containing proteins to initiate a cellular signaling pathway (Carraway and Cantley, 1994; Olayioye et al., 1998). The HER-2/neu gene encodes a 185 kDa transmembrane receptor tyrosine kinase. Unlike the other epidermal growth factor receptors (EGFR), HER-2/neu has an intrinsic tyrosine kinase activity that activates PI(3)K in the absence of ligand (Fruman et al., 1998; Figure 1). PI(3)K consists of a regulatory subunit (p85) that binds to an activated growth factor/cytokine receptor and undergoes phosphorylation, which results in the activation of its catalytic subunit (p110) (Rodriguez-Viciano et al., 1996). PI(3)K phosphorylates phosphoinositides at the 3'-position of the inositol ring, and its major lipid product is phosphatidylinositol 3,4,5-triphosphate (PIP₃) (Rameh and Cantley, 1999). PIP₃ facilitates the recruitment of Akt to the plasma membrane through binding with the pleckstrin homology (PH) domain of Akt (Rameh and Cantley, 1999). Akt is activated by phosphoinositide-dependent kinase-1 (PDK1) through phosphorylation at threonine 308 and serine 473 (Alessi et al., 1997). A number of pro-apoptotic proteins have been identified as direct Akt substrates, including BAD, caspase-9, and Forkhead transcription factors (Brunet et al., 1999; Cardone et al., 1998; Cross et al., 1995; Datta et al., 1997; del Peso et al., 1997; Hetman et al., 2000; Zhao et al., 2004). The pro-apoptotic function of these molecules is

suppressed upon phosphorylation by Akt. Previous studies also show that Akt induces the degradation of I κ B by promoting IKK α activity and subsequently stimulating the nuclear translocation of NF- κ B (Ozes et al., 1999). Our lab (Nam et al., 2002) and Panka et al. (2001) reported that the PI(3)K-Akt-NF- κ B pathway may regulate the expression of FLICE-inhibitory protein (FLIP), an anti-apoptotic molecule. We identified the mechanisms by which HER-2/neu affects TRAIL-induced apoptotic death.

TRAIL is a type II integral membrane protein belonging to the TNF family. TRAIL is a 281-amino acid protein, related most closely to a Fas/APO-1 ligand. Like Fas ligand (FasL) and TNF, the C-terminal extracellular region of TRAIL (amino acids 114-281) exhibits a homotrimeric subunit structure (Pitti et al., 1996). However, unlike FasL and TNF, several studies reveal that TRAIL induces apoptosis in a wide variety of tumor cells, but does not cause toxicity to most normal cells (Ashkenazi and Dixit, 1998). Several studies also reveal that TRAIL, which is constitutively expressed on murine natural killer cells in the liver, plays an important role in surveillance of tumor metastasis (Takeda et al., 2001). The apoptotic signal of TRAIL is transduced by binding to the death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5), which are members of the TNF receptor superfamily. Both DR4 and DR5 contain a cytoplasmic death domain that is required for TRAIL receptor-induced apoptosis. TRAIL also binds to TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2), which act as decoy receptors by inhibiting TRAIL signaling (Pan et al., 1997a; Pan et al., 1997b; Sheridan et al., 1997; Walczak et al., 1997; Degli-Esposti et al., 1997a; Degli-Esposti et al., 1997b; Marsters et al., 1997). Unlike DR4 and DR5, DcR1 does not have a cytoplasmic domain and DcR2 retains a cytoplasmic fragment containing a truncated form of the consensus death domain motif (Pan et al., 1997a). Recent studies suggest that DRs and DcRs interact through their extracellular domains to form homometric and/or heterometric complexes (Lee et al., 2005). Differential sensitivity between normal and tumor cells to TRAIL has been explained by the presence of a high concentration of the decoy receptors in normal cells (Gura, 1997; Ashkenazi and Dixit, 1999). However, this hypothesis has been challenged based on the results showing poor correlations between DR4, DR5, and DcR1 expression and sensitivity to TRAIL-induced apoptosis in normal and cancerous breast cell lines (Keane et al., 1999; Leblanc and Ashkenazi, 2003). This discrepancy indicates that other factors such as death inhibitors (FLIP, FAP-1, Bcl-2, Bcl-X_L, or IAP) or pro-apoptotic molecules (Bax, Bad, Bim, or Bid) are also involved in the differential sensitivity to TRAIL. TRAIL binding to death receptors is thought to result in conformational changes that expose a binding surface for Fas-associated death domain (FADD), an adaptor protein (Kischkel et al., 2000; Thomas et al., 2004). TRAIL triggers apoptosis by recruiting the apoptosis initiator procaspase-8 through the adaptor FADD (Bodmer et al., 2000). Caspase-8 can directly activate downstream effector caspases including procaspase-3, -6, and -7 (Cohen, 1997). Caspase-8 also cleaves Bid and triggers mitochondrial damage that in turn leads to cytochrome *c* release (Li et al., 1997). Cytochrome *c* in the cytoplasm binds to Apaf-1, which then permits recruitment of procaspase-9. Caspase-9 cleaves and activates procaspase-3 (Slee et al., 1999). Thus, TRAIL produces apoptosis. On the other hand, the PI(3)K-Akt-NF- κ B pathway counteracts this effect, because NF- κ B promotes the expression of certain Bcl-2 family, IAP family and FLIP family proteins: (a) The activation of caspases is counteracted by anti-apoptotic molecules of the Bcl-2 family (Bcl-2, Bcl-X_L), because the Bcl-2 family proteins heterodimerize with pro-apoptotic members of the Bcl-2 family (Bax, Bak) and interfere with release of cytochrome *c* by pore-forming proteins (Bid, Bik) (Gross et al., 1999); (b) Members of the inhibitor of apoptosis (IAP) family (c-IAP1, c-IAP2, XIAP) can directly bind and inhibit activation of caspases including caspase-3, -7 and -9 (Roy et al., 1997); (c) Previous studies have shown that several FLIP splice variants exist on the mRNA level, but two endogenous forms, FLIP_L and FLIP_S, are detected on the protein level (Shu et al., 1997; Tschopp et al., 1998). Krueger et al. (2001) reported that FLIP_L and FLIP_S prevent caspase-8 activation at different levels of procaspase-8 processing at the DISC (death-inducing signaling complex). Thus, the expression of these Bcl-2 family, IAP family, and FLIP family proteins is promoted by NF- κ B, a family of dimeric transcription factors (Chen et al., 2000). The NF- κ B family of proteins, including NF- κ B1, NF- κ B2, RelA, RelB, and c-Rel, can form homo- and heterodimers *in vitro*, except for RelB. In mammals, the most widely distributed NF- κ B is a heterodimer composed of p50 and p65 (also called RelA) subunits (Baeuerle and Baltimore, 1989). NF- κ B activity is

regulated by the I κ B family of proteins which interacts with and sequesters the transcription factor in the cytoplasm. I κ B proteins become phosphorylated by the multisubunit I κ B kinase (IKK) complex, which subsequently targets I κ B for ubiquitination and degradation by the 26S proteasome (Zandi and Karin, 1999). We investigated the mechanisms by which the HER-2/neu-PI(3)K-Akt-NF- κ B signal counteracts the extent of TRAIL-induced apoptotic death.

Previous studies have revealed a link between HER-2/neu signaling and cyclooxygenase-2 (COX-2) expression (Vadlamudi et al., 1999; Kiguchi et al., 2001). Overexpression of HER-2/neu leads to elevated levels of COX-2 through a MAPK-dependent pathway (Subbaramaiah et al., 2002). COX-2 catalyzes the formation of prostaglandin E₂ (PGE₂) which stimulates CYP19 gene expression (Subbaramaiah et al., 2006). Cytochrome P450 aromatase (aromatase), a product of the CYP19 gene, catalyzes the synthesis of estrogens from androgens (Dubey et al., 2005). Given the significance of estrogen synthesis in hormone-dependent prostate carcinogenesis (Ho et al., 2006), inhibiting aromatase by quercetin results in decreased estrogen biosynthesis and leads to antiestrogenic effects which may be important in prostate cancer.

Body:

HER-2/neu gene expression and TRAIL cytotoxicity

To determine a correlation between HER-2/neu gene expression and TRAIL cytotoxicity, human prostatic adenocarcinoma LNCaP and DU-145 cells were treated with various concentrations of TRAIL (0-1000 ng/ml). Cell survival was analyzed by the trypan blue exclusion assay (Fig. 1B) and the intracellular level of HER-2/neu was measured by western blot analysis (Fig. 1A). Figure 1 shows that LNCaP cells containing a relatively high level of HER-2/neu are resistant to TRAIL. In contrast, DU-145 cells containing a relatively low level of HER-2/neu are sensitive to TRAIL. These results suggest that HER-2/neu protects cells from TRAIL-induced cytotoxicity.




Figure 1. Expression of HER-2/neu and TRAIL sensitivity in LNCaP and DU-145 cells. **A:** Cells were lysed and subjected to western blot analysis with an anti-HER-2/neu antibody. **B:** LNCaP (□) or DU-145 (■) cells were exposed to TRAIL (0-1000 ng/ml) for 4 hr and survival was analyzed by the trypan blue exclusion assay.

Akt activity and TRAIL-induced apoptotic death

In this grant proposal, we hypothesize that HER-2/neu-enhanced resistance to TRAIL is mediated through the Akt pathway. Previous studies have shown that phosphorylation of Thr-308 and Ser-473 is required for Akt activity. Data from western blot analysis shows that LNCaP cells have relatively high Akt activity (Fig. 2). In contrast, DU-145 cells have relatively low Akt activity (Fig. 2).




Figure 2. Basal Akt activity in LNCaP and DU-145 cells. Lysates containing equal amounts of protein (20 μ g) were separated by SDS-PAGE and immunoblotted with anti-Akt antibody (Akt) or anti-phospho-S473 Akt antibody (pAkt). **Actin**, actin is shown as an internal standard.

We examined whether quercetin, which is known to inhibit the HER-2/neu associated PI(3)K-Akt signal transduction pathway, can sensitize HER-2/neu overexpressing cancers to TRAIL-induced cell death. First, we investigated how quercetin inhibits the HER-2/neu associated PI(3)K-Akt signal transduction pathway. Figure 3 shows that quercetin induced dephosphorylation (inactivation) of Akt, but not PI(3)K.




Figure 3. Effect of quercetin on PI(3)K-Akt signal transduction pathway associated kinases. LNCaP cells were treated for 4 h with 200 μM quercetin in the presence or absence of 50 ng/ml TRAIL, and then harvested. Equal amounts of protein (20 μg) were separated by SDS-PAGE and immunoblotted with anti-phospho-PI(3)K, anti-PI(3)K, anti-phospho-PDK-1, anti-PDK-1, anti-phospho(S473)-Akt, anti-phospho(T308)-Akt, or anti-Akt antibody.

Next, we investigated the effect of quercetin on TRAIL-induced cytotoxicity. LNCaP cells were treated with TRAIL in the presence or absence of quercetin. Little or no cytotoxicity was observed with quercetin (10-200 μM) alone (Fig. 4A). TRAIL in combination with quercetin significantly increased TRAIL-induced cytotoxicity (Fig. 4B). TdT-mediated dUTP Nick end labeling (TUNEL) assay showed that apoptotic death was enhanced during combined treatment with TRAIL and quercetin (Fig. 4C).




Figure 4. Effect of quercetin on TRAIL-induced cytotoxicity in human prostate adenocarcinoma LNCaP cells. (A) Cells were treated for 4 h with various concentrations of quercetin (10-200 μM). (B) Cells were treated with various concentrations of TRAIL (10-200 ng/ml) in the presence or absence of 200 μM quercetin. Cell survival was determined by the trypan blue exclusion assay. Error bars represent standard error of the mean (SEM) from three separate experiments. (C) Cells were treated for 4 h with TRAIL (200 ng/ml) in the presence or absence of 200 μM quercetin. After treatment, apoptosis was detected by the TUNEL assay. Apoptotic cells are indicated by arrows. Con, untreated control; TRAIL, 200 ng/ml TRAIL; Quercetin, 200 μM quercetin; TRAIL + Quercetin, 200 ng/ml TRAIL in the presence of 200 μM quercetin.

Effect of quercetin on TRAIL-induced proteolytic cleavage of PARP and activation of caspases

Additional studies were designed to examine whether the combination of quercetin and TRAIL treatment in LNCaP cells enhances poly (ADP-ribose) polymerase (PARP) cleavage, the hallmark feature of apoptosis. Previous studies show that PARP (116 kDa) is cleaved yielding a characteristic 85 kDa fragment in the presence of TRAIL alone in human prostate adenocarcinoma DU-145 cells (Lee et al., 2004). Figure 5 shows that the cleavage of PARP was not observed during treatment with either

Figure 6 Effect of quercetin, LY294002, or wortmannin on kinases (A & B), and TRAIL-induced cytotoxicity (C) in LNCaP cells. (A & B) Cells were treated for 1 h with LY294002 (LY; 2-20 μ M), wortmannin (Wort; 20-200 nM), or 200 μ M quercetin. Equal amounts of protein (20 μ g) were separated by SDS-PAGE and immunoblotted as described in Materials and Methods. Actin is shown as an internal standard. Con, untreated control cells. (C) Cells were pretreated with 200 μ M quercetin, 50 μ M LY294002, or 1 μ M wortmannin for 30 min and then treated with TRAIL (200 ng/ml) for 4 h. Cell survival was determined by the trypan blue exclusion assay. Error bars represent standard error of the mean (SEM) from three separate experiments.

Effect of combined treatment with TRAIL and quercetin on the level of TRAIL receptor family and anti-apoptotic proteins

Previous studies demonstrate that increased DR5 levels induced by genotoxic agents (Sheikh et al., 1998; Chinnaiyan et al., 2000) or decreased FLIP expression induced by glucose deprivation (Nam et al., 2002) is responsible for increasing TRAIL cytotoxicity. Thus we examined whether changes in the amounts of TRAIL receptors and anti-apoptotic proteins are associated with the promotion of apoptosis by TRAIL in combination with quercetin. LNCaP cells were treated with TRAIL (50 ng/ml) in the presence of quercetin (10-200 μ M) for 4 hr. Data from western blot analysis reveal that the combined treatment did not significantly alter the levels of DR4, DR5, DcR2, FLIP_L, FLIP_S, Bcl-2, Bcl-xL, cIAP-1, and cIAP-2 (Fig. 7). Quercetin alone also did not significantly change the levels of TRAIL receptors and anti-apoptotic proteins (Fig. 7).




Figure 7. Intracellular levels of TRAIL receptors (A) or anti-apoptotic proteins (B) during treatment with TRAIL in the presence or absence of quercetin. LNCaP cells were treated for 4 hr with 50 or 200 ng/ml TRAIL in the presence or absence of various concentrations of quercetin (10-200 μ M). Equal amounts of protein (20 μ g) were separated by SDS-PAGE and immunoblotted with anti-DR4, anti-DR5, anti-DcR2, anti-FLIP_L, anti-FLIP_S, anti-Bcl-2, anti-Bcl-xL, anti-cIAP-1, or anti-cIAP-2. Actin was used to confirm the amount of protein loaded in each lane.

Key research accomplishments:

Our experimental results revealed that quercetin effectively promotes TRAIL-induced apoptosis. Western blot analysis showed that combined treatment with TRAIL and quercetin did not change the levels of TRAIL receptors (DR4, DR5, and DcR2) or anti-apoptotic proteins (FLIP, IAP, and Bcl-2). However, quercetin promotes the dephosphorylation of Akt. Thus, our data reveals that quercetin enhances TRAIL-induced cytotoxicity by activating caspases and inhibiting phosphorylation of Akt.

Reportable Outcomes and Conclusions:

We conclude that quercetin enhances TRAIL-induced cytotoxicity by inhibiting phosphorylation of the PI3K-Akt pathway-associated kinases and phosphatases. We believe that the outcome of these studies provides information to support the development and clinical application of TRAIL in combination with quercetin for the treatment of prostate cancer patients.

Publications:

Kim, K.M., and Lee, Y.J. (2005) Role of HER-2/neu signaling in sensitivity to tumor necrosis factor-related apoptosis-inducing ligand: enhancement of TRAIL-mediated apoptosis by amiloride. *J Cell Biochem.*, 96:376-389.

Kim, K.M., and Lee, Y.J. (2005) Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway. *Oncogene.*, 24:355-366.

Kim, Y.H., and Lee, Y.J. (2006) Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity. *J Cell Biochem.*, 98:1284-1295.

Kim, Y.H., and Lee, Y.J. (2007) TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. *J Cell Biochem.*, 100:998-1009.

References

Adhami, V.M., Ahmad, N., and Mukhtar, H. (2003) Molecular targets for green tea in prostate cancer prevention. *J. Nutr.*, 133:2417S-2424S.

Alessi, D., James, S., Downes, C., Holmes, A., Gaffney, P., Reese, C., and Cohen, P. (1997) 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the *Drosophila* DSTPK61 kinase. *Curr. Biol.*, 7: 261-269.

Alia, M., Ramos, S., Mateos, R., Granado-Serrano, A.B., Bravo, L., and Gova, L. (2005) Quercetin protects human hepatoma HepG2 against oxidative stress induced by tertbutyl hydroperoxide. *Toxicol. Appl. Pharmacol.*, In press.

Arai, Y., Tatsuhiro, T., and Yoshida, O. (1997) c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. *Prostate*, 30:195-201.

Ashkenazi, A., and Dixit, V.M. (1998) Death receptors: signaling and modulation. *Science*, 281: 1305-1308.

Askkenazi, A., and Dixit, V.M. (1999) Apoptosis control by death and decoy receptors. *Curr. Opin. Cell Biol.*, 11:255-260.

Baeuerle, P.A., and Baltimore, D. (1989) 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. *Gene Dev.*, 3:1689-1698.

Bartlett, J.M., Brawley, D., Grigor, K., Munro, A.F., Dunne, B., Edwards, J. Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. *J. Pathol.*, 205:522-529.

- Biggs, W.H., III, Meisenhelder, J., Hunter, T., Cavenee, W.K., and Arden, K.C. (1999) Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. *Proc. Natl. Acad. Sci.*, 96:7421-7426.
- Blackburn, R.V., Galoforo, S.S., Berns, C.M., Armour, E.P., McEachern, D., Corry, P.M., and Lee, Y.J. (1997) Comparison of tumor growth between hsp25- and hsp27-transfected murine L929 cells in nude mice. *Int. J. Cancer*, 72, 871-877.
- Bodmer, J.L., Holler, N., Reynard, S., Vinciguerra, P., Schneider, P., Juo, P., Blenis, J., Tschopp, J. (2000) TRAIL receptor-2 signals apoptosis through FADD and caspase-8. *Nat. Cell Biol.*, 2, 241-243.
- Bors, W., Heller, W., Michel, C., and Saran, M. (1994) Flavonoids as antioxidants: rate constants for reaction with oxygen radicals. *Methods Enzymol.*, 234:420-429.
- Brunet, A., Bonni, A., Zigmond, M.J., Lin, M.Z., Juo, P., Hu, L.S., Anderson, M.J., Arden, K.C., Blenis, J., and Greenberg, M.E. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell*, 96:857-868.
- Bui, N.T., Livolsi, A., Peyron, J.F., and Prehn, J.H.M. (2001) Activation of nuclear factor kappaB and Bcl-x survival gene expression by nerve growth factor requires tyrosine phosphorylation of IkappaBalpha. *J. Cell Biol.*, 152:753-763.
- Cardone, M.H., Roy, N., Stennicke, H.R., Salvesen, G.S., Franke, T.F., Stanbridge, E., Frisch, S., and Reed, J.C. (1998) Regulation of cell death protease caspase-9 by phosphorylation. *Science*, 282:1318-1321.
- Carraway, K.L. 3rd, and Cantley, L.C. (1994) A new acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. *Cell*, 78:5-8.
- Chen, C., Edelstein, L.C., and Gelinas, C. (2000) The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). *Mol. Cell. Biol.*, 20:2687-2695.
- Chinnaiyan, A.A., Prasad, U., Shankar, S., Hamstra, D.A., Shanaiah, M., Chenevert, T.L., Ross, B.D., and Rehemtulla, A. (2000) Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. *Proc. Natl. Acad. Sci. USA*, 97:1754-1759.
- Cohen, G.M. (1997) Caspases: the executioners of apoptosis. *Biochem. J.* 326: 1-16.
- Craft, N., Shostak, Y., Carey, M., and Sawyers, C.L. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. *Nature Med.*, 5:280-285.
- Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., and Hemmings, B.A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature*, 378:785-789.
- Da Silva, E.L., Piskula, M.K., Yamamoto, N., Moon, J.H., and Terao, J. (1998) Quercetin metabolites inhibit copper ion-induced lipid peroxidation in rat plasma. *FEBS Lett.*, 430:405-408.

- Datta, S.R., Brunet, A., and Greenberg, M.E. (1999) Cellular survival: a play in three Akts. *Genes Dev.*, 13:2905-2927.
- Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M.E. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell*, 91:231-241.
- Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., Goodwin, and R. G. (1997b) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. *Immunity*. 7, 813-820.
- Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C. P., DuBose, R. F., Goodwin, R. G., and Smith, C. A. (1997a) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. *J. Exp. Med.*, 186, 1165-1170.
- del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. (1997) Interleukine-3-induced phosphorylation of BAD through the protein kinase Akt. *Science*, 278:687-689.
- Dubey, R.K., Jackson, E.K., Gillespie, D.G., Rosselli, M., Barchiesi, F., Krust, A., Keller, H., Zacharia, L.C., and Imthurn, B. (2005) Cytochromes 1A1/1B1- and catechol-O-methyltransferase-derived metabolites mediate estradiol-induced antimitogenesis in human cardiac fibroblast. *J. Clin. Endocrinol. Metab.*, 90:247-255.
- Eng, M.H., Charles, L.G., Ross, B.D., Chrisp, C.E., Pienta, K.J., Greenberg, N.M., Hsu, C.X., and Sanda, M.G. (1999) Early castration reduces prostatic carcinogenesis in transgenic mice. *Urology*, 54:1112-1119.
- Fruman, D.A., Meyers, R.E., and Cantley, L.C. (1998) Phosphoinositide kinases. *Annu. Rev. Biochem.*, 67:481-507.
- Gross, A., McDonnell, J.M., and Korsmeyer, S.J. (1999) BCL-2 family members and the mitochondria in apoptosis. *Genes Dev.*, 13:1899-1911.
- Gura, T. (1997) How TRAIL kills cancer cells, but not normal cells. *Science*, 277-768.
- Hetman, M., Cavanaugh, J.E., Kimeiman, D., and Xia, Z. (2000) Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. *J. Neurosci.*, 20:2567-2574.
- Ho, S.M., Tang, W.Y., Belmonte de Frausto, J., Prins, G.S. (2006) Developmental exposure to estradiol and bisphenol a increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. *Cancer Res.*, 66:5624-5632.
- Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., Takagi, M., Matsumoto, K., Miyazono, K., and Gotoh, Y. (1997) Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. *Science*, 275:90-94.
- Kandaswami, C., and Middleton, E., Jr. (1994) Free radical scavenging and antioxidant activity of plant flavonoids. *Adv. Exp. Med. Biol.*, 366:351-376.
- Kandel, E.S., and Hay, N. (1999) The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. *Exp. Cell Res.*, 253:210-229.

- Kaplan-Lefko, P.J., Chen, T.M., Ittmann, M.M., Barrios, R.J., Ayala, G.E., Huss, W.J., Maddison, L.A., Foster, B.A., and Greenberg, N.M. (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. *Prostate*, 55:219-237.
- Keane, M. M., Ettenberg, S. A., Nau, M. M., Russell, E. K., and Lipkowitz, S. (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. *Cancer Res.*, 59, 734-741.
- Kennedy, S.G., Wagner, A.J., Conzen, S.D. Jordan, J., Bellacosa, A., Tsichlis, P.N., and Hay, N. (1997) The PI3-kinase/AKT signaling pathway delivers an anti-apoptotic signals. *Genes Dev.*, 11:70-1713.
- Kiguchi, K., Carbajal, S., Chan, K., Beltran, L., Ruffino, L., Shen, J., Matsumoto, T., Yoshimi, N., and DiGiovanni, J. (2001) Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. *Cancer Res.*, 61:6971-6976.
- Kim, A.H., Khursigara, G., Sun, X., Franke, T.F., and Chao, M.V. (2001) Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. *Mol. Cell. Biol.*, 21:893-901.
- Kischkel, F.C., Lawrence, D.A., Chuntharapai, A., Schow, P., Kim, K.J., and Ashkenazi, A. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. *Immunity*, 12, 611-620.
- Klapper, L.N., Waterman, H., Sela, M., and Yarden, Y. (2000) Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. *Cancer Res.*, 60:3384-3388.
- Krueger, A., Schmitz, I., Baumann, S., Krammer, P.H., and Kirchhoff, S. (2001) Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. *J. Biol. Chem.*, 276:20633-20640.
- Kwak, Y.T., Guo, J., Shen, J., and Gaynor, R.B. (2000) Analysis of domains in the IKK α and IKK β proteins that regulate their kinase activity. *J. Bio. Chem.*, 275:14752-14759.
- LeBlanc, H.N., and Ashkenazi, A. (2003) Apo2L/TRAIL and its death and decoy receptors. *Cell Death Differ.*, 10:66-75.
- Lee, H.W., Lee, S.H., Lee, H.W., Ryu, Y.W., Kwon, M.H., and Kim, Y.S. (2005) Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors. *Biochem. Biophys. Res. Commun.*, 330:1205-1212.
- Lee, M.W., Park, S.C., Kim, J.H., Kim, I.K., Han, K.S., Kim, K.Y., Lee, W.B., Jung, Y.K., and Kim, S.S. (2002) The involvement of oxidative stress in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in HeLa cells. *Cancer Lett.*, 182:75-82.
- Lee, Y.J., Song, J.J., Kim, J.H., Kim, H.R.C., and Song, Y.K. (2004) Low extracellular pH augments TRAIL-induced apoptotic death through the mitochondria-mediated caspase signal transduction pathway. *Expt. Cell. Res.*, 293:129-143.
- Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S.M., Ahmad, M., Alnemri, E.S., Wang, X. (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell*, 91, 479-489.

- Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., and Ashkenazi, A. (1997) A novel receptor for Apo2L/TRAIL contains a truncated death domain. *Curr. Biol.*, 7, 1003-1006.
- Matter, W.F., Brown, R.F., and Vlahos, C.J. (1992) The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. *Biochem. Biophys. Res. Commun.*, 186:624-631.
- Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., and Tschopp, J. (2001) NF-kappaB signals induce the expression of c-FLIP. *Mol. Cell. Biol.*, 21:5299-5305.
- Middleton, E., Jr., and Kandaswami, C. (1993) The impact of plant flavonoids on mammalian biology: implication for immunity, inflammation and cancer, p. 619-645. In J. B. Harborne (ed.), *The flavonoids: advances in research since 1986*. Chapman & Hall, London, United Kingdom.
- Nair, M.P., Kandaswami, C., Mahajan, S., Chadha, K.C., Chawda, R., Nair, H., Kumar, N., Nair, R.E., and Schwartz, S.A. (2002) The flavonoid, quercetin, differentially regulates Th-1 (IFN γ) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. *Biochim. Biophys. Acta*, 1593:29-36.
- Nakashio, A., Fujita, N., Rokudai, S., Sato, S., and Tsuruo, T. (2000) Prevention of phosphatidylinositol 3'-kinase-Akt survival pathway during topotecan-induced apoptosis. *Cancer Res.*, 60:5303-5309.
- Nam, S.Y., Amoscato, A.A., and Lee, Y.J. (2002) Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. *Oncogene*, 21:337-346.
- Olayioye, M.A., Graus-Porta, D., Beerli, R.R., Rohrer, J., Gay, B., and Hynes, N.E. (1998) ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. *Mol. Cell. Biol.*, 18:5042-5051.
- Osman, I., Scher, H.I., Drobnjak, M., Verbel, D., Morris, M., Agus, D., Ross, J.S., and Cordon-Cardo, C. (2001) HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. *Clin. Cancer Res.*, 7:2643-2647.
- Ozes, O.N., Mayo, L.D., Gustin, J.A., Pfeffer, S.R., Pfeffer, L.M., and Donner, D.B. (1999) NF-kappaB activation by tumor necrosis factor requires the Akt serine-threonine kinase. *Nature*, 401, 82-85.
- Pan, G., Ni, J., Wei, Y. F., Yu, G., Gentz, R., and Dixit, V. M. (1997b) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science*, 277, 815-818.
- Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., and Dixit, V. M. (1997a) The receptor for the cytotoxic ligand TRAIL. *Science*, 276, 111-113.
- Panka, D.J., Mano, T., Suhara, T., Walsh, K., and Mier, J. (2001) Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. *J. Biol. Chem.*, 276:6893-6896.
- Raghow, S., Kuliyeve, E., Steakley, M., Greenberg, N., and Steiner, M.S. (2000) Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. *Cancer Res.*, 60:4093-4097.

- Rameh, L.E., and Cantley, L.C. (1999) The role of phosphoinositide 3-kinase lipid products in cell function. *J. Biol. Chem.*, 274:8347-8350.
- Rodriguez-Viciana, P., Marte, B., Warne, P., and Downward, J. (1996) Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.*, 351:225-231.
- Ross, J.A., and Kasum, C.M. (2002) Dietary flavonoids: Bioavailability, metabolic effects, and safety. *Annu. Rev. Nutr.* 22:19-34.
- Roy, N., Deveraux, Q.L., Takahashi, R., Salvesen, G.S., and Reed, J.C. (1997) The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. *EMBO J.*, 16:6914-6925.
- Sheikh, M.S., Burns, T.F., Huang, Y., Wu, G.S., Amundson, S., Brooks, K.S., Fornace, A.J. Jr, el-Deiry, W.S. (1998) p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α . *Cancer Res.*, 58:1593-1598.
- Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P., and Ashkenazi, A. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science*, 277:818-821.
- Sheu, M.L., Ho, F.M., Chao, K.F., Kuo, M.L., and Liu, S.H. (2004) Activation of phosphoinositide 3-kinase in response to high glucose leads to regulation of reactive oxygen species-related nuclear factor-kB activation and cyclooxygenase-2 expression in mesangial cells. *Mol. Pharmacol.*, 66:187-196.
- Shu, H.B., Halpin, D.R., and Goeddel, D.V. (1997) Casper is a FADD- and caspase-related inducer of apoptosis. *Immunity*, 6:751-763.
- Signoretti, S., Montironi, R., Manola, J., Altimari, A., Tam, C., Bubley, G., Balk, S., Thomas, G., Kaplan, I., Hlatky, L., Hahnfeldt, P., Kantoff, P., and Loda, M. (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. *J. Natl. Cancer Inst.*, 92:1918-1925.
- Singh, S.V., Srivastava, S.K., Choi, S., Lew, K.L., Xiao, D., Zeng, Y., Johnson, C.S., Trump, D.L., and Lee, Y.J. (2005) Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. *J. Biol. Chem.*, 280:19911-19924.
- Slee, E.A., Harte, M.T., Kluck, R.M., Wolf, B.B., Casiano, C.A., Newmeyer, D.D., Wang, H.G., Reed, J.C., Nicholson, D.W., Alnemri, E.S., Green, D.R., Martin, S.J. (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. *J. Cell Biol.*, 144: 281-92.
- Subbaramaiah, K., Howe, L.R., Port, E.R., Brogi, E., Fishman, J., Liu, C.H., Hla, T., Hudis, C., and Dannenberg, A.J. (2006) HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. *Cancer Res.*, 66:5504-5511.
- Subbaramaiah, K., Norton, L., Gerald, W., and Dannenberg, A.J. (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. *J. Biol. Chem.*, 277:18649-18657.

- Suzuki, I., I. Hayashi, T. Takaki, D. S. Groveman, and Fujimiya, Y. (2002) Antitumor and anticytopenic effects of aqueous extracts of propolis in combination with chemotherapeutic agents. *Cancer Biother. Radiopharm.*, 17:553-562.
- Takeda, K., Hayakawa, Y., Smyth, M.J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., Okumura, K. (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. *Nat. Med.*, 7:94-100.
- Thomas, L.R., Henson, A., Reed, J.C., Salsbury, F.R., Thorburn, A. (2004) Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD. *J. Biol. Chem.*, 279:32780-32785.
- Tschopp, J., Irmeler, M., and Thome, M. (1998) Inhibition of Fas death signals by FLIPS. *Curr. Opin. Immunol.*, 10:552-558.
- Vadlamudi, R., Mandal, M., Adam, L., Steinbach, G., Mendelsohn, J., and Kumar, R. (1999) Regulation of cyclooxygenase-2 pathway by HER2 receptor. *Oncogene*, 18:305-314.
- Vijayababu, M.R., Kanagaraj, P., Arunkumar, A., Ilangovan, R., Aruldas, M.M., and Arunakaran, J. (2005) Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. *J. Cancer Res. Clin. Oncol.*, July 28:1-7
- Vulcain, E., Goupy, P., Caris-Veyrat, C., and Dangles, O. (2005) Inhibition of the metmyoglobin-induced peroxidation of linoleic acid by dietary antioxidants: Action in the aqueous vs. lipid phase. *Free Radic Res.*, 39:547-563.
- Walczak, H., Degli-Esposti, M. A., Johnson, R. S., Smolak, P. J., Waugh, J. Y., Boiani, N., Timour, M. S., Gerhart, M. J., Schooley, K. A., Smith, C. A., Goodwin, R. G., and Rauch, C. T. (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. *EMBO J.*, 16: 5386-5397.
- Wang, C.Y., Mayo, M.W., Korneluk, R.G., Goeddel, D.V., and Baldwin Jr., A.S. (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. *Science.*, 281:1680-1683.
- Wang, H. K. (2000) The therapeutic potential of flavonoids. *Expert Opin. Investig. Drugs*, 9:2103-2119.
- Xiao, D., Choi, S., Johnson, D.E., Vogel, V.G., Johnson, C.S., Trump, D.L., Lee, Y.J., and Singh, S.V. (2004) Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-jun N-terminal kinase and extracellular signal-regulated kinase-mediated phosphorylation of Bcl-2. *Oncogene*, 23, 5594-5606.
- Xiao, D., Choi, S., Lee, Y.J., and Singh, S.V. (2005) Role of mitogen-activated protein kinases in phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells. *Mol Carcinog.*, 43:130-140..
- Xing, N., Chen, Y., Mitchell, S.H., Young, C.Y. (2001) Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. *Carcinogenesis*, 22:409-414.

- Yamamoto, K.H., Ichijo, H., and Korsmeyer, S.J. (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. *Mol. Cell. Biol.*, 19:8469-8478.
- Yoshizumi, M., Tsuchiya, K., Kirima, K., Kyaw, M., Suzaki, Y., and Tamaki, T. (2001) Quercetin inhibits Shc- and phosphatidylinositol 3-kinase-mediated c-Jun N-terminal kinase activation by angiotensin II in cultured rat aortic smooth muscle cells. *Mol. Pharmacol.*, 60:656-665.
- Yuan, H., Gong, A., and Young, C.Y.F. (2005) Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. *Carcinogenesis*, 26:793-801.
- Yuan, H., Pan, Y., and Young, C.Y.F. (2004) Overexpression of c-Jun induced by quercetin and reverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. *Cancer Lett.*, 213:155-163.
- Zandi, E., and Karin, M. (1999) Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex. *Mol. Cell. Biol.*, 19:4547-4551.
- Zha, J., Harada, H., Yang, E., Jockel, J., and Korsmeyer, S.J. (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). *Cell*, 87:619-628.
- Zhao, S., Konopleva, M., Cabreira-Hansen, M., Xie, Z., Hu, W., Milella, M., Estrov, Z., Mills, G.B., and Andreeff, M. (2004) Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. *Leukemia*, 18:267-275.
- Zhou, B.P., Hu, M.C., Miller, S.A., Yu, Z., Xia, W., Lin, S.Y., and Hung, M.C. (2000) HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. *J. Biol. Chem.*, 275:8027-8031.